Earnings release · LLY
ELI LILLY & Co · Filed · SEC Form 8-K, Item 2.02
Revenue increased 48% year on year to $23.0 billion, and EPS climbed 33% to $7.94. Growth in both sales and earnings is the combination investors usually look for first. Management raised its outlook, and guidance changes often matter more to the market than the quarter just reported because they reflect expectations for the periods ahead.
Written automatically by Stocknote's note engine from the figures on this page and the company's previous release. Every number in this note is checked against those figures. Not investment advice.
$23.0 billion +48% vs a year ago
…Revenue in Q2 2026 increased 48% to $23.0 billion driven primarily by Mounjaro and Zepbound volume.…
$7.94 +33% vs a year ago
…Q2 2026 EPS increased by 26% to $7.94 on a reported basis and increased by 33% to $8.38 on a non-GAAP basis.…
Guidance raised
…Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress…
Lilly’s revenue grew 39% and guidance rose, but two drugs supplied 88% of growth, price fell 15%, and $4.57 a share of acquired R&D held non-GAAP EPS growth to 7%.
Forensic equity research on US stocks. No spam, unsubscribe anytime.
